CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

Clinical Advances in Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma CME/CE
Faculty: David S. Ettinger, MD; Nicholas J. Vogelzang, MD; Mark A. Socinski, MD
Disclosures

Release Date: April 21, 2005; Valid for credit through April 21, 2006

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity "Clinical Advances in Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma" was originally offered as live events certified for CME.

Contents of This CME/CE Activity
This activity is offered in two formats. Please choose one of the versions:

    Flash Version
    (A multimedia presentation with synchronized audio, slides and transcript.)
    Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version.
    Download the Macromedia Flash Player 5 plug-In:

    Get Flash 5

    --OR--

    Slides with transcript and RealAudio:

  1. Therapeutic Progress in Metastatic NSCLC
    by David S. Ettinger, MD
    Non-Small Cell Lung Cancer: Treatment Paradigms
    Survival Rates Across Various Studies
    Other Dosing Issues: Regimen, Timing, Whom to Treat?
    Summing Up Survival, Benefits/Risks, and Options in Therapy
    Gefitinib, Erlotinib in Non-Small Cell Lung Cancer
    Gefitinib, Erlotinib in Non-Small Cell Lung Cancer (cont'd)
    Additional Treatment Trial Findings
    Second-Line Treatment Trial Findings
    Practice Guidelines

  2. Therapeutic Progress in Malignant Mesothelioma
    by Nicholas J. Vogelzang, MD
    Malignant Mesothelioma: Introduction
    Diagnosis and Staging of Malignant Mesothelioma
    Treatment Approaches
    Chemotherapy in Mesothelioma
    Pemetrexed
    Phase III Study of Pemetrexed: Introduction
    Phase III Study of Pemetrexed: Patients
    Phase III Study of Pemetrexed: Survival, Response, Adverse Events
    Phase III Study of Pemetrexed: Additional Findings
    Additional Trials
    Conclusions

  3. Therapeutic Progress in Locally Advanced NSCLC
    by Mark A. Socinski, MD
    Non-Small Cell Lung Cancer: Introduction
    Non-Small Cell Lung Cancer: Stages
    Radiation Therapy vs Chemotherapy/Radiation Therapy
    The CHART and HART Trials
    Radiotherapy Dosing, Sequencing, and Other Issues
    Studies of Concurrent Chemotherapy/Radiation Therapy
    Studies of Concurrent Chemotherapy/Radiation Therapy (cont'd)
    Future Directions and Summary

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The materials presented here do not necessarily reflect the views of Medscape, PeerPoint Medical Education Institute, LLC, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2005 the PeerPoint Medical Education Institute, LLC.
Lilly
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME/CE Information
 
PeerPoint
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The PeerPoint Medical Education Institute, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The PeerPoint Medical Education Institute, LLC designates this educational activity for a maximum of 2.0 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
The American Association of Critical Care Nurses (AACN) has approved this program for 2.0 contact hours, CERP Category A, file number 00012699.


This program meets Oncology Nursing Society guidelines for quality educational content. ONS endorsement does not constitute medical advice. Healthcare providers should exercise their own independent medical judgment.
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.